Reference trademark issue [Regulatives / Guidelines]

posted by rajasekharkakarla – India, 2018-07-24 09:05 (912 d 01:06 ago) – Posting: # 19087
Views: 1,991

Dear All,

I prepared protocol for Mesalamine delayed-release tablets 1.2 gm for USFDA submission, i written reference name as Lialda™ (mesalamine) delayed release tablets 1.2 gm with trademark TM and the protocol was approved by EC. But as per COA it is mentioned as Lialda®, there is change in trademark. kindly suggest whether i need to go with ammendment/not.


Complete thread:

 Admin contact
21,308 posts in 4,444 threads, 1,488 registered users;
online 4 (0 registered, 4 guests [including 3 identified bots]).
Forum time: Thursday 09:12 CET (Europe/Vienna)

Politicians use statistics like drunkards use lampposts:
not for illumination, but for support.    attributed to Hans Kuhn

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz